

Cassiopea S.p.A. Via Cristoforo Colombo, 1 20020 – Lainate (MI)

Object: Proposals for the Ordinary General Shareholders' meeting of Cassiopea S.p.A

Proposal related to the item n. 2 of the Agenda of Ordinary General Assembly: 2a) decision on the number of members of the new Board of Directors, 2b) decision on the duration of the tenure of the new Board of Directors, 2c) decision on the compensation of the new Board of Directors

In addition to the list of candidates already submitted, Cosmo Pharmaceuticals N.V. submit the following proposals:

2a) that the new board of directors of the Company is composed of no. 5 members,

2b) that the new board of directors remains in office for one year until the approval of the financial statements as at 31 December 2021 and

2c) that the overall annual compensation for the entire Board of directors is equal to EUR 205,500.00.

Proposal related to the item n. 3 of the Agenda of Ordinary General Assembly

Cosmo Pharmaceuticals N.V., based on the favourable opinion expressed by the Comitato sul Controllo della Gestione, proposes to confirm to BDO Italia Spa the mandate for the statutory audit of the accounts of the Company for the financial years $2021 \cdot 2023$, for an annual fee of Eur 25,000.00.

Dublin, 20 April 2021

Cosmo Pharmaceuticals NV

COSMO Pharmaceuticals N.V.

Registered Office: Riverside II, Sir John Rogerson's Quay Dublin 2, Ireland Tel +353 (I) 8170370 info@cosmopharma.com www.cosmopharma.com

Registered in Netherlands Reg. Co. #65617738

Branch Registered in Ireland Reg. Co. #908460 VAT #IE3419733KH